Funds and ETFs Orion Oyj

ORNBV

FI0009014377

Name	Weight	AuM	1st Jan change	Investor Rating
XACT NORDIC HIGH DIVIDEND LOW VOLATILITY UCITS ETF - SEK	2.96%	0 M€	+9.57%
SELIGSON & CO OMX HELSINKI 25 UCITS ETF - EUR	2.87%	0 M€	+4.19%
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.35%	0 M€	+3.32%
FRANKLIN LIBERTYQ EUROPEAN EQUITY UCITS ETF - EUR	0.32%	3 M€	+9.95%	-
INDEXIQ FACTORS SUSTAINABLE EMU EQUITY UCITS ETF - EUR	0.24%	0 M€	+9.82%
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF - CAD	0.14%	14 M€	+5.66%	-
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF (CAD-HEDGED) - CAD	0.14%	5 M€	+10.09%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.11%	0 M€	+7.69%	-
AMUNDI MSCI EUROPE EX UK UCITS ETF (C) - EUR	0.07%	6 M€	-.--%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	0.03%	6 M€	-.--%
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.02%	10 M€	-3.35%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - EUR	0.02%	0 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - CHF	0.02%	0 M€	+8.31%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - B - USD	0.02%	0 M€	+11.14%
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.02%	276 M€	+11.40%	-
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.01%	1,166 M€	+0.26%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.01%	607 M€	+0.05%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.01%	0 M€	+8.19%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.01%	284 M€	-.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.01%	0 M€	+18.61%
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.01%	206 M€	-.--%
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.01%	0 M€	+3.25%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	0 M€	+7.83%	-

Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Orion Oyj

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

36.4 EUR

Average target price

39 EUR

Spread / Average Target

+7.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORION OYJ	-7.31%	5.51B
ELI LILLY AND COMPANY	+32.36%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	361B
MERCK & CO., INC.	+19.46%	330B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	239B
NOVARTIS AG	+6.68%	204B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	168B

Other Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 08:59:37 08/05/2024 pm IST			Pre-market 11:40:11 am
36.4 ^EUR	+0.80%		36.8	+1.10%

07/05	Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025	CI
26/04	Orion Corporation Announces Appointments to Nomination Committee	CI